Infant Bacterial Therapeutics publicerar årsredovisning för 2021
31 mars 2022 02h00 HE
|
Infant Bacterial Therapeutics AB
Pressmeddelande 31 mars 2022 Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2021. Årsredovisningen finns tillgänglig på IBTs hemsida,...
FINANCIAL REPORT Q4 2021 - Jøtul AS
28 févr. 2022 04h00 HE
|
Jøtul AS
The Jøtul Group (representing, as at 31 December 2021, Jøtul AS together with its subsidiaries) is one of the three largest suppliers of fireplaces in Europe and a significant player in North...
Infant Bacterial Therapeutics AB (publ), (IBT) bokslutskommuniké 1 januari – 31 december 2021
04 févr. 2022 14h00 HE
|
Infant Bacterial Therapeutics AB
Pressmeddelande den 4 februari, 2022 VD kommenterar IBT:s pågående avgörande fas III-studie syftar till att ta fram data som förbättrar prematura spädbarns möjligheter att överleva. Det görs genom...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
04 févr. 2022 14h00 HE
|
Infant Bacterial Therapeutics AB
Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is...
FINANCIAL REPORT Q3 2021 - Jøtul AS
24 nov. 2021 08h55 HE
|
Jøtul AS
The Jøtul Group (representing, as at 30 September 2021, Jotul Holdings SA together with its subsidiaries) is one of the three largest suppliers of fireplaces in Europe and a significant player in...
12 ReTech Corporation Released its Financial Report for the Quarter Ended September 30, 2021.
22 nov. 2021 08h30 HE
|
12 Retech Corporation
Shows 180.3% Revenue Improvement Over Prior Comparable Period Results and Generates a GAAP Net Loss of $5.8 million. Las Vegas, NV, Nov. 22, 2021 (GLOBE NEWSWIRE) -- 12 ReTech...
Sprout AI Inc. Q3 Financial Report
01 nov. 2021 08h30 HE
|
Sprout AI Inc.
VANCOUVER, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Sprout AI Inc. (“Sprout AI” or the “Company”) (CSE: SPRT) has filed its unaudited interim Third Quarter (Q3) Financial Statement (FS)...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 september 2021
29 oct. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför IBT en stor fas III-studie (“The Connection Study”) vilket är den sista studien i vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414, som...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
29 oct. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the...
Jotul Holdings SA - Interim financial report for the half-year ended 30. June 2021
30 août 2021 10h00 HE
|
Jøtul AS
In the first half of 2021, the Jotul Group reached a consolidated loss of MNOK 54.1 (H1 2020: loss of MNOK 68.5). The operating loss totaled MNOK 1.2 in H1 2021 (H1 2020: loss of MNOK 60.1). The 2021...